Literature DB >> 28754228

Post-treatment surveillance of thyroid cancer.

L Y Wang1, I Ganly2.   

Abstract

An increased incidence of differentiated thyroid cancer (DTC) has resulted in an increased population of thyroid cancer survivors requiring ongoing disease surveillance. Our institution's risk-adapted surveillance strategy is based on a contemporary understanding of disease biology, guided by analysis of prognostic factors and balanced application of available surveillance modalities. The goal of this strategy is to detect recurrent disease early, identify patients who would benefit from further treatment and reduce over investigation of low-risk patients. This article describes our center's risk-stratified approach to the postoperative surveillance of patients with differentiated thyroid cancer with reference to the recent 2015 American Thyroid Association management guidelines.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness; Epidemiology; Recurrence; Surgery; Survival; Thyroid neoplasm

Mesh:

Substances:

Year:  2017        PMID: 28754228      PMCID: PMC7422645          DOI: 10.1016/j.ejso.2017.07.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  46 in total

1.  Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.

Authors:  Yuri E Nikiforov; Raja R Seethala; Giovanni Tallini; Zubair W Baloch; Fulvio Basolo; Lester D R Thompson; Justine A Barletta; Bruce M Wenig; Abir Al Ghuzlan; Kennichi Kakudo; Thomas J Giordano; Venancio A Alves; Elham Khanafshar; Sylvia L Asa; Adel K El-Naggar; William E Gooding; Steven P Hodak; Ricardo V Lloyd; Guy Maytal; Ozgur Mete; Marina N Nikiforova; Vania Nosé; Mauro Papotti; David N Poller; Peter M Sadow; Arthur S Tischler; R Michael Tuttle; Kathryn B Wall; Virginia A LiVolsi; Gregory W Randolph; Ronald A Ghossein
Journal:  JAMA Oncol       Date:  2016-08-01       Impact factor: 31.777

2.  Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.

Authors:  Volkert B Wreesmann; Iain J Nixon; Michael Rivera; Nora Katabi; Frank Palmer; Ian Ganly; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Snehal G Patel; Ronald A Ghossein
Journal:  Thyroid       Date:  2015-03-31       Impact factor: 6.568

3.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

4.  Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.

Authors:  Laura Y Wang; Andrew W Smith; Frank L Palmer; R Michael Tuttle; Azhar Mahrous; Iain J Nixon; Snehal G Patel; Ian Ganly; James A Fagin; Laura Boucai
Journal:  Thyroid       Date:  2014-12-16       Impact factor: 6.568

Review 5.  Contemporary post surgical management of differentiated thyroid carcinoma.

Authors:  H Tala; R M Tuttle
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-06-01       Impact factor: 4.126

6.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

7.  Current thyroid cancer trends in the United States.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

8.  Cost-effectiveness analysis of papillary thyroid cancer surveillance.

Authors:  Laura Y Wang; Benjamin R Roman; Jocelyn C Migliacci; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

9.  Intermediate-risk group for differentiated carcinoma of thyroid.

Authors:  A R Shaha; T R Loree; J P Shah
Journal:  Surgery       Date:  1994-12       Impact factor: 3.982

Review 10.  Differentiated thyroid carcinoma: defining new paradigms for postoperative management.

Authors:  Cosimo Durante; Giuseppe Costante; Sebastiano Filetti
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

View more
  5 in total

1.  Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy.

Authors:  Danielli Matsuura; Avery Yuan; Victoria Harris; Ashok R Shaha; R Michael Tuttle; Snehal G Patel; Jatin P Shah; Ian Ganly
Journal:  Thyroid       Date:  2022-01       Impact factor: 6.568

2.  Circular RNA circ_0000644 promotes papillary thyroid cancer progression via sponging miR-1205 and regulating E2F3 expression.

Authors:  Chunlei Nie; Jihua Han; Wen Bi; Zhilin Qiu; Lili Chen; Jiawei Yu; Rui Pang; Bo Liu; Ruinan Sheng; Jiewu Zhang
Journal:  Cell Cycle       Date:  2021-12-17       Impact factor: 4.534

3.  Prognostic Impact of Direct 131I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study.

Authors:  José F Carrillo; Rafael Vázquez-Romo; Margarita C Ramírez-Ortega; Liliana C Carrillo; Edgar Gómez-Argumosa; Luis F Oñate-Ocaña
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-29       Impact factor: 5.555

4.  BRAFV600E Induction in Thyrocytes Triggers Important Changes in the miRNAs Content and the Populations of Extracellular Vesicles Released in Thyroid Tumor Microenvironment.

Authors:  Ophélie Delcorte; Catherine Spourquet; Pascale Lemoine; Jonathan Degosserie; Patrick Van Der Smissen; Nicolas Dauguet; Axelle Loriot; Jeffrey A Knauf; Laurent Gatto; Etienne Marbaix; James A Fagin; Christophe E Pierreux
Journal:  Biomedicines       Date:  2022-03-23

Review 5.  Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer.

Authors:  Massimiliano Pacilio; Miriam Conte; Viviana Frantellizzi; Maria Silvia De Feo; Antonio Rosario Pisani; Andrea Marongiu; Susanna Nuvoli; Giuseppe Rubini; Angela Spanu; Giuseppe De Vincentis
Journal:  Diagnostics (Basel)       Date:  2022-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.